Physician profile
Amanda E Geiter
NPI 1699284133
$2,972.79
in general payments reported to CMS, 2019-2025
29 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.24 · 2022: $77.55 · 2023: $53.79 · 2024: $1,520 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.01 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $571.55 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $291.27 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $258.95 | 2024-2025 | Sotyktu |
| Innovation Technologies INC | $197.55 | 2024 | Irrisept |
| Genzyme Corporation | $186.57 | 2024-2025 | |
| Integra Lifesciences Corporation | $173.05 | 2021-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Sun Pharmaceutical Industries INC. | $147.13 | 2024-2025 | |
| Leo Pharma INC. | $119.20 | 2024-2025 | Adbry, Anzupgo |
| Incyte Corporation | $108.42 | 2025 | Opzelura |
| Abbvie INC. | $102.43 | 2024-2025 | |
| Lilly USA, LLC | $82.81 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Scientific Affairs, LLC | $77.25 | 2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $72.93 | 2024 | Libtayo, Dupixent |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Arcutis Biotherapeutics, INC. | $69.49 | 2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $61.84 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $60.92 | 2024-2025 | Nemluvio |
| Pfizer INC. | $59.32 | 2024-2025 | |
| Almirall LLC | $48.75 | 2024 | Klisyri |
| Dermavant Sciences, INC. | $40.31 | 2024 | Vtama |
| Botanix Sb INC | $35.46 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $27.58 | 2024 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.02 | 2025 | Spevigo |
| Amgen INC. | $21.26 | 2025 | Otezla |
| Medline Industries Lp | $18.83 | 2023 | |
| Biofrontera INC. | $18.34 | 2025 | |
| Molnlycke Health Care US, LLC | $11.70 | 2023 | Mepitel Ag, Mepilex Transfer Ag, Mepilex Ag |
| Mayne Pharma Commercial LLC | $6.00 | 2025 | |
| Organon LLC | $5.86 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Geiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.